Results 171 to 180 of about 87,925 (315)

Ida‐FLAG plus imatinib mesylate‐induced molecular remission in a patient with chemoresistant Ph¹(+) acute myeloid leukemia [PDF]

, 2003
Nora‐Athina Viniou, Theodoros P. Vassilakopoulos, Xanthi Giakoumi, Marina Mantzouranis, Gerassimos A. Pangalis   +4 more
openalex   +1 more source

Nanoparticles Combining Host‐Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum

Advanced Therapeutics, Volume 8, Issue 4, April 2025.
This study investigates the combination of host‐directed therapeutics (HDT) with antibiotics in a single polymeric micelle based on polypept(o)ides for the therapy of Mycobacterium tuberculosis (Mtb) and ‐marinum (Mm) infections. When the HDT and antibiotic are co‐encapsulated, it significantly reduces bacterial burden in cells and improves overall ...
Gabriela Schäfer, Dongdong Bi, Federico Fenaroli, Andrew M. Thompson, Anno Saris, Matthias Barz   +5 more
wiley   +1 more source

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib [PDF]

, 2003
Barbara Waßmann, Roman Pfeifer, Urban Scheuring, Anja Binckebanck, Nicola Gökbuget, Johannes Atta, Patrick T. Bruck, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta B. Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann   +17 more
openalex   +1 more source

Imatinib in breast milk [PDF]

Annals of Hematology, 2009
Kronenberger, Roland, Schleyer, Eberhard, Bornhäuser, Martin, Ehninger, Gerhard, Gattermann, Norbert, Blum, Sabine   +5 more
openaire   +3 more sources

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase [PDF]

, 2003
Thomas B. Sneed, Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Mary Beth Rios, B. Nebiyou Bekele, Xian Zhou, Debra Resta, William Wierda, Stefan Faderl, Francis J. Giles, Jorge E. Cortés   +11 more
openalex   +1 more source

Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers

Cancer Medicine, Volume 14, Issue 8, April 2025.
ABSTRACT Background Genetic testing and sequencing technologies offer a comprehensive understanding of cancer genetics, providing rapid and cost‐effective solutions. In particular, these advanced technologies play an important role in assessing the complexities of the rare cancer types affecting several systems including the bone, endocrine, digestive,
Joviana Farhat, Lara Alzyoud, Mohammad AlWahsh, Animesh Acharjee, Basem Al‐Omari   +4 more
wiley   +1 more source

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Biologics: Targets & Therapy, 2009
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML ...
Radhakrishnan Ramchandren, Charles A Schiffer   +1 more
doaj  

Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status [PDF]

, 2003
Debra Resta, Martin S. Tallman, Mary Beth Riley, John L. Frater, Brian J. Druker, LoAnn Peterson, Daina Variakojis, Mary Ann Hrisinko   +7 more
openalex   +1 more source

Imatinib-induced gynecomastia

Indian Journal of Endocrinology and Metabolism, 2019
Nitin Kapoor, Nambiathayil Aboobacker Fouzia, Kripa Elizabeth Cherian, Thomas V Paul, Pragya Gupta   +4 more
openaire   +4 more sources

Benefits and Limitations of Real‐World Patient‐Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers

Cancer Medicine, Volume 14, Issue 8, April 2025.
ABSTRACT Background Toxicity monitoring should be modernized to include real‐world patient‐reported data. However, little is known about how stakeholders view the incorporation of real‐world patient‐reported toxicity symptoms into guidelines. This gap hinders the development of a sustained learning healthcare environment and limits the incorporation of
Y. Smit, L. Verweij, A. Currie, J. J. W. M. Janssen, E. F. M. Posthuma, A. Dekker, R. P. M. G. Hermens, N. M. A. Blijlevens   +7 more
wiley   +1 more source